Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve.
- 作者列表："Romanski PA","Bortoletto P","Rosenwaks Z","Schattman GL
STUDY QUESTION:Will a delay in initiating IVF treatment affect pregnancy outcomes in infertile women with diminished ovarian reserve? SUMMARY ANSWER:A delay in IVF treatment up to 180 days does not affect the live birth rate for women with diminished ovarian reserve when compared to women who initiate IVF treatment within 90 days of presentation. WHAT IS KNOWN ALREADY:In clinical practice, treatment delays can occur due to medical, logistical or financial reasons. Over a period of years, a gradual decline in ovarian reserve occurs which can result in declining outcomes in response to IVF treatment over time. There is disagreement among reproductive endocrinologists about whether delaying IVF treatment for a few months can negatively affect patient outcomes. STUDY DESIGN, SIZE, DURATION:A retrospective cohort study of infertile patients in an academic hospital setting with diminished ovarian reserve who started an IVF cycle within 180 days of their initial consultation and underwent an oocyte retrieval with planned fresh embryo transfer between 1 January 2012 and 31 December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS:Diminished ovarian reserve was defined as an anti-Müllerian hormone (AMH) <1.1 ng/ml. In total, 1790 patients met inclusion criteria (1115 immediate and 675 delayed treatment). Each patient had one included cycle and no subsequent data from additional frozen embryo transfer cycles were included. Since all cycle outcomes evaluated were from fresh embryo transfers, no genetically tested embryos were included. Patients were grouped by whether their cycle started 1-90 days after presentation (immediate) or 91-180 days (delayed). The primary outcome was live birth (≥24 weeks of gestation). A subgroup analysis of more severe forms of diminished ovarian reserve was performed to evaluate outcomes for patients with an AMH <0.5 and for patients >40 years old with an AMH <1.1 ng/ml (Bologna criteria for diminished ovarian reserve). Logistic regression analysis, adjusted a priori for patient age, was used to estimate the odds ratio (OR) with a 95% CI. All pregnancy outcomes were additionally adjusted for the number of embryos transferred. MAIN RESULTS AND THE ROLE OF CHANCE:The mean ± SD number of days from presentation to IVF start was 50.5 ± 21.9 (immediate) and 128.8 ± 25.9 (delayed). After embryo transfer, the live birth rate was similar between groups (immediate: 23.9%; delayed: 25.6%; OR 1.08, 95% CI 0.85-1.38). Additionally, a similar live birth rate was observed in a subgroup analysis of patients with an AMH <0.5 ng/ml (immediate: 18.8%; delayed: 19.1%; OR 0.99, 95% CI 0.65-1.51) and in patients >40 years old with an AMH <1.1 ng/ml (immediate: 12.3%; delayed: 14.7%; OR 1.21, 95% CI 0.77-1.91). LIMITATIONS, REASONS FOR CAUTION:There is the potential for selection bias with regard to the patients who started their IVF cycle within 90 days compared to 91-180 days after initial consultation. In addition, we did not include patients who were seen for initial evaluation but did not progress to IVF treatment with oocyte retrieval; therefore, our results should only be applied to patients with diminished ovarian reserve who complete an IVF cycle. Finally, since we excluded patients who started their IVF cycle greater than 180 days from their first visit, it is not known how such a delay in treatment affects pregnancy outcomes in IVF cycles. WIDER IMPLICATIONS OF THE FINDINGS:A delay in initiating IVF treatment in patients with diminished ovarian reserve up to 180 days from the initial visit does not affect pregnancy outcomes. This observation remains true for patients who are in the high-risk categories for poor response to ovarian stimulation. Providers and patients should be reassured that when a short-term treatment delay is deemed necessary for medical, logistic or financial reasons, treatment outcomes will not be affected. STUDY FUNDING/COMPETING INTEREST(S):No financial support, funding or services were obtained for this study. The authors do not report any potential conflicts of interest. TRIAL REGISTRATION NUMBER:Not applicable.
研究问题: 延迟开始IVF治疗会影响卵巢储备减少的不孕妇女的妊娠结局吗？ 摘要答案: 与在90天内开始IVF治疗的女性相比，IVF治疗延迟180天不会影响卵巢储备减少的女性的活产率。 已知的是: 在临床实践中，由于医疗、后勤或经济原因，可能发生治疗延迟。经过几年的时间，卵巢储备逐渐下降，这可能导致随着时间的推移，IVF治疗的结果下降。生殖内分泌学家对于延迟几个月的IVF治疗是否会对患者的结局产生负面影响存在分歧。 研究设计、规模、持续时间: 一项回顾性队列研究，研究对象是在2012年1月1日至20 18年12月31日期间，在学术医院中卵巢储备功能下降的不孕患者，这些患者在初次就诊后180天内开始IVF周期，并接受了计划新鲜胚胎移植的卵母细胞提取。 参与者/材料，背景，方法: 卵巢储备功能下降被定义为抗苗勒管激素 (AMH) <1.1 ng/ml。总共有1790例患者符合纳入标准 (1115立即治疗和675延迟治疗)。每个患者有一个包括的周期，没有包括来自额外的冷冻胚胎移植周期的后续数据。由于评价的所有周期结果均来自新鲜胚胎移植，因此不包括遗传测试胚胎。根据他们的周期是在出现后1-90天 (立即) 还是91-180天 (延迟) 开始对患者进行分组。主要结局为活产 (≥ 24周妊娠).进行了更严重形式的卵巢储备减少的亚组分析，以评估AMH <0.5的患者和AMH <1.1 ng/ml的> 40岁患者的结局 (Bologna卵巢储备减少的标准)。采用Logistic回归分析，根据患者年龄进行先验调整，以95% CI估计比值比 (OR)。所有妊娠结局均额外调整了移植胚胎的数量。 主要结果和机会的作用: 从就诊到IVF开始的平均 ± SD天数为50.5 ± 21.9 (立即) 和128.8 ± 25.9 (延迟)。胚胎移植后，两组的活产率相似 (即刻: 23.9%; 延迟: 25.6%; OR 1.08，95% CI 0.85-1.38)。此外，在对AMH <0.5 ng/ml的患者 (立即: 18.8%; 延迟: 19.1%; OR 0.99，95% CI 0.65-1.51) 和AMH <1.1 ng/ml的> 40岁患者 (立即: 12.3%; 延迟: 14.7%; 或1.21，95% CI 0.77-1.91)。 限制，谨慎的原因: 对于在90天内开始IVF周期的患者，与最初咨询后91-180天相比，存在选择偏倚的可能性。此外，我们没有纳入接受初始评估但未进行IVF治疗并取卵的患者; 因此，我们的结果应仅适用于完成IVF周期的卵巢储备功能下降的患者.最后，由于我们排除了从第一次就诊开始IVF周期超过180天的患者，因此不知道这种治疗延迟如何影响IVF周期中的妊娠结局。 研究结果的更广泛含义: 卵巢储备减少患者开始IVF治疗延迟至初次就诊180天不影响妊娠结局。这一观察结果仍然适用于对卵巢刺激反应不良的高风险类别的患者。提供者和患者应该放心，当由于医疗、后勤或经济原因而认为短期治疗延迟是必要的时，治疗结果不会受到影响。 研究资金/竞争利益: 本研究没有获得财政支持、资金或服务。作者没有报告任何潜在的利益冲突。 试用注册号: 不适用。
METHODS::1. Glutathione S-transferases (GST) and cytochrome P450s (CYPs) are xenobiotic metabolizing enzymes participating in the protection of cell. The present study aimed to investigate the relationship between polymorphisms of glutathione S-transferase M1 (GSTM1) null, glutathione S-transferase T1 (GSTT1) null, glutathione S-transferase P1 (GSTP1) Ile105Val, cytochrome P450 1A2 (CYP1A2) 734 C→A, cytochrome P450 2D6 (CYP2D6) 1934 G→A and male infertility.2. A total of 306 azoospermic or oligozoospermic infertile men and 129 normozoospermic or fertile controls were enrolled in the study. Multiplex polymerase chain reaction (PCR) or PCR-restriction fragment length polymorphism methods were used for genotyping. There was a significant relationship between male infertility and CYP2D6 GG genotype (p < 0.001). CYP1A2 AA genotype was slightly higher in the infertile group (p = 0.056).3. There was no association between GSTT1 null polymorphisms and male infertility (p = 0.068), GSTM1 null (p = 0.843) and GSTP1 Ile105Val (p = 0.192) genes. GSTM1 null genotype frequency was higher in azoospermic men (p = 0.009). Men carrying CYP1A2 AA genotype had higher risk of infertility risk (OR = 3.14; %95 CI = 1.16-8.54) in the smoker group.4. Our results demonstrated that polymorphisms of CYP2D6 and CYP1A2 may play a role in idiopathic male infertility in our sample population.
METHODS:PURPOSE:This study evaluated the effect of counseling based on the choice theory on irrational parenthood cognition (IPC)- and marital quality in infertile women. DESIGN AND METHODS:This randomized controlled trial was conducted on 50 primary infertile women in Zanjan, Iran. Stratified block randomization was used to allocate participants to groups. The intervention group received counseling, but the control group received routine care. Data were collected using the IPC and marital relationships quality based on the Glasser's choice theory. FINDINGS:A statistically significant difference was found between the groups in IPC (P = 0.005), but the difference in marital quality was not statically significant ( P = 0.085). PRACTICE IMPLICATIONS:Counseling can be used for decreasing IPC, but more interventions are needed to increase marital quality.
METHODS::A decrease in cancer deaths has resulted in the possibility of child bearing for many young adult cancer survivors. Most antitumor treatment modalities are detrimental to female fertility, and methods for fertility preservation before gonadotoxic treatment, including cryopreservation of oocytes, embryos and ovarian tissue, have therefore been developed. This review focuses on the ovarian function of cancer patients, the safety and efficacy of fertility preservation methods, and the pregnancy outcomes of these patients. Breast cancer and hematological tumors constitute the majority of cancers in reproductive-aged female oncology patients. Ovarian function may not be impacted by breast cancer cells, while in patients with hematological malignancies, decreases in anti-Müllerian hormone and antral follicle counts have been demonstrated. In most cases, patients can undergo ovarian stimulation without delaying treatment, and a new stimulation protocol known as dual stimulation, which may be more efficient, has now been developed. Birth outcomes are also acceptable in cancer patients.